Meridian Bioscience Inc. (VIVO)

9.45
0.50 5.50
NASDAQ : Health Technology
Prev Close 8.95
Open 8.93
Day Low/High 8.82 / 9.46
52 Wk Low/High 8.82 / 19.84
Volume 262.41K
Avg Volume 271.80K
Exchange NASDAQ
Shares Outstanding 42.71M
Market Cap 376.71M
EPS 0.60
P/E Ratio 14.70
Div & Yield N.A. (N.A)

Latest News

The Cannabis ETF (THCX) Rebalance Further Diversifies Portfolio

The Cannabis ETF (THCX) Rebalance Further Diversifies Portfolio

THCX Adds Companies Focused on CBD, Ancillary Services and Canadian Retail Market

Meridian Bioscience Reports Third Quarter 2019 Operating Results

Meridian Bioscience Reports Third Quarter 2019 Operating Results

CINCINNATI, Ohio, July 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019.

Meridian Bioscience To Hold Third Quarter 2019 Financial Results Conference Call On July 30, 2019

Meridian Bioscience To Hold Third Quarter 2019 Financial Results Conference Call On July 30, 2019

CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019.

Meridian Bioscience Becomes Oversold (VIVO)

Meridian Bioscience Becomes Oversold (VIVO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, And Provides Fiscal 2019 Guidance For Pending Acquisition

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, And Provides Fiscal 2019 Guidance For Pending Acquisition

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019.

Meridian Bioscience Announces Agreement To Acquire Business Of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

Meridian Bioscience Announces Agreement To Acquire Business Of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, ALXN, ATUS, BHF, CEQP, DLR, EDU, F, LKQ, MTX, WNC Downgrades: AKO.A, AKO.B, BABY, BC, BPRN, BRQS, EHTH, FNWB, IKNX, JNPR, KRA, MMLP, OMCL, TRN, UTHR, VIVO Initiations: BWB Read on to get TheStreet Quant Ratings' detailed report:

VIVO Crosses Above Average Analyst Target

VIVO Crosses Above Average Analyst Target

In recent trading, shares of Meridian Bioscience Inc. have crossed above the average analyst 12-month target price of $13.33, changing hands for $13.39/share.

Meridian Bioscience Breaks Below 200-Day Moving Average - Notable For VIVO

Meridian Bioscience Breaks Below 200-Day Moving Average - Notable For VIVO

In trading on Tuesday, shares of Meridian Bioscience Inc. crossed below their 200 day moving average of $16.40, changing hands as low as $14.44 per share.

Meridian Bioscience Becomes Oversold (VIVO)

Meridian Bioscience Becomes Oversold (VIVO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ex-Div Reminder For Meridian Bioscience

Ex-Div Reminder For Meridian Bioscience

Looking at the universe of stocks we cover at Dividend Channel, on 2/1/19, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 2/14/19.

Meridian Bioscience Reaches Analyst Target Price

Meridian Bioscience Reaches Analyst Target Price

In recent trading, shares of Meridian Bioscience Inc. have crossed above the average analyst 12-month target price of $16.33, changing hands for $16.45/share.

VIVO Makes Notable Cross Below Critical Moving Average

VIVO Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Meridian Bioscience Inc. crossed below their 200 day moving average of $15.80, changing hands as low as $15.01 per share.

Meridian Bioscience Is Now Oversold (VIVO)

Meridian Bioscience Is Now Oversold (VIVO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of July 2019 Options Trading For Meridian Bioscience (VIVO)

First Week Of July 2019 Options Trading For Meridian Bioscience (VIVO)

Investors in Meridian Bioscience Inc. saw new options begin trading this week, for the July 2019 expiration.

Bullish Two Hundred Day Moving Average Cross - VIVO

Bullish Two Hundred Day Moving Average Cross - VIVO

In trading on Monday, shares of Meridian Bioscience Inc. crossed above their 200 day moving average of $15.05, changing hands as high as $15.23 per share.

Notable Two Hundred Day Moving Average Cross - VIVO

Notable Two Hundred Day Moving Average Cross - VIVO

In trading on Wednesday, shares of Meridian Bioscience Inc. crossed below their 200 day moving average of $15.00, changing hands as low as $14.95 per share.

Reminder - Meridian Bioscience (VIVO) Goes Ex-Dividend Soon

Reminder - Meridian Bioscience (VIVO) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 8/9/18, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 8/20/18.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCR, CIZN, EMCI, HWKN, MEI, NEWM, RECN, STN, VIVO, WEBK Downgrades: CHS, CIG.C, CTHR, GURE, HIBB, VIV Initiations: ASMB, NOVN Read on to get TheStreet Quant Ratings' detailed report:

Insiders Were Right: VIVO Makes New 52-Week High

Insiders Were Right: VIVO Makes New 52-Week High

In trading on Monday, shares of Meridian Bioscience Inc. touched a new 52-week high of $16.50/share.

Meridian Bioscience Reaches Analyst Target Price

Meridian Bioscience Reaches Analyst Target Price

In recent trading, shares of Meridian Bioscience Inc. have crossed above the average analyst 12-month target price of $15.00, changing hands for $15.05/share.

VIVO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/30/2018 settlement date, and Meridian Bioscience Inc. is one of the most shorted stocks of the Russell 3000, based on 17.58 "days to cover" versus the median component at 5.00.

Ex-Div Reminder For Meridian Bioscience (VIVO)

Looking at the universe of stocks we cover at Dividend Channel, on 5/4/18, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 5/17/18.

Meridian Bioscience Reaches Analyst Target Price

Meridian Bioscience Reaches Analyst Target Price

In recent trading, shares of Meridian Bioscience Inc. have crossed above the average analyst 12-month target price of $15.00, changing hands for $15.05/share.

VIVO: Insiders vs. Shorts

VIVO: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/12/2018 settlement date, and Meridian Bioscience Inc. is one of the most shorted stocks of the Russell 3000, based on 13.90 "days to cover" versus the median component at 4.53.

Meridian Bioscience About To Put More Money In Your Pocket (VIVO)

Meridian Bioscience About To Put More Money In Your Pocket (VIVO)

Looking at the universe of stocks we cover at Dividend Channel, on 2/2/18, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 2/15/18.

TheStreet Quant Rating: C (Hold)